Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone

Robert S Krouse, R. E. Royal, G. Heywood, B. D. Weintraub, D. E. White, S. M. Steinberg, S. A. Rosenberg, D. J. Schwartzentruber

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The purpose of this prospective study was to determine the incidence of thyroid dysfunction in cancer patients receiving immunotherapy with interleukin-2 (IL-2) alone, and to assess the relationship of hypothyroidism to clinical response. A cohort of 281 consecutive patients with metastatic melanoma or renal carcinoma were treated with IL-2 alone from July 1, 1989 until June 30, 1993. The majority (n = 216) received high-dose IL-2 and the remainder (n = 65) received low-dose therapy. Thyroid function was measured before, during, and after immunotherapy. Forty-one percent of initially euthyroid patients developed thyroid dysfunction after starting high-dose IL- 2-alone therapy. The most common abnormality was hypothyroidism, occurring in 35% of patients, although moderate or severe hypothyroidism requiring thyroid hormone replacement occurred in 9% of patients. Hypothyroidism was related to duration of IL-2 therapy and was not associated with clinical response. Hyperthyroidism developed in 7% of previously euthyroid patients receiving high-dose IL-2. Overall, the incidence of thyroid dysfunction was similar in the high- and low-dose IL-2 regimens. In conclusion, thyroid dysfunction is a common sequela of IL-2 therapy. Thyroid function should be measured routinely in cancer patients receiving IL-2-based treatment. It is recommended that thyroid hormone replacement be given to patients with moderate or severe hypothyroidism.

Original languageEnglish (US)
Pages (from-to)272-278
Number of pages7
JournalJournal of Immunotherapy
Volume18
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Interleukin-2
Melanoma
Thyroid Gland
Carcinoma
Kidney
Hypothyroidism
Thyroid Hormones
Immunotherapy
Therapeutics
Incidence
Hyperthyroidism
Neoplasms
Prospective Studies

Keywords

  • Hyperthyroidism
  • Hypothyroidism
  • IL-2
  • Melanoma
  • Renal carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Krouse, R. S., Royal, R. E., Heywood, G., Weintraub, B. D., White, D. E., Steinberg, S. M., ... Schwartzentruber, D. J. (1995). Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. Journal of Immunotherapy, 18(4), 272-278.

Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. / Krouse, Robert S; Royal, R. E.; Heywood, G.; Weintraub, B. D.; White, D. E.; Steinberg, S. M.; Rosenberg, S. A.; Schwartzentruber, D. J.

In: Journal of Immunotherapy, Vol. 18, No. 4, 1995, p. 272-278.

Research output: Contribution to journalArticle

Krouse, RS, Royal, RE, Heywood, G, Weintraub, BD, White, DE, Steinberg, SM, Rosenberg, SA & Schwartzentruber, DJ 1995, 'Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone', Journal of Immunotherapy, vol. 18, no. 4, pp. 272-278.
Krouse, Robert S ; Royal, R. E. ; Heywood, G. ; Weintraub, B. D. ; White, D. E. ; Steinberg, S. M. ; Rosenberg, S. A. ; Schwartzentruber, D. J. / Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. In: Journal of Immunotherapy. 1995 ; Vol. 18, No. 4. pp. 272-278.
@article{d10ec402598b47249a4a5cf35000f919,
title = "Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone",
abstract = "The purpose of this prospective study was to determine the incidence of thyroid dysfunction in cancer patients receiving immunotherapy with interleukin-2 (IL-2) alone, and to assess the relationship of hypothyroidism to clinical response. A cohort of 281 consecutive patients with metastatic melanoma or renal carcinoma were treated with IL-2 alone from July 1, 1989 until June 30, 1993. The majority (n = 216) received high-dose IL-2 and the remainder (n = 65) received low-dose therapy. Thyroid function was measured before, during, and after immunotherapy. Forty-one percent of initially euthyroid patients developed thyroid dysfunction after starting high-dose IL- 2-alone therapy. The most common abnormality was hypothyroidism, occurring in 35{\%} of patients, although moderate or severe hypothyroidism requiring thyroid hormone replacement occurred in 9{\%} of patients. Hypothyroidism was related to duration of IL-2 therapy and was not associated with clinical response. Hyperthyroidism developed in 7{\%} of previously euthyroid patients receiving high-dose IL-2. Overall, the incidence of thyroid dysfunction was similar in the high- and low-dose IL-2 regimens. In conclusion, thyroid dysfunction is a common sequela of IL-2 therapy. Thyroid function should be measured routinely in cancer patients receiving IL-2-based treatment. It is recommended that thyroid hormone replacement be given to patients with moderate or severe hypothyroidism.",
keywords = "Hyperthyroidism, Hypothyroidism, IL-2, Melanoma, Renal carcinoma",
author = "Krouse, {Robert S} and Royal, {R. E.} and G. Heywood and Weintraub, {B. D.} and White, {D. E.} and Steinberg, {S. M.} and Rosenberg, {S. A.} and Schwartzentruber, {D. J.}",
year = "1995",
language = "English (US)",
volume = "18",
pages = "272--278",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone

AU - Krouse, Robert S

AU - Royal, R. E.

AU - Heywood, G.

AU - Weintraub, B. D.

AU - White, D. E.

AU - Steinberg, S. M.

AU - Rosenberg, S. A.

AU - Schwartzentruber, D. J.

PY - 1995

Y1 - 1995

N2 - The purpose of this prospective study was to determine the incidence of thyroid dysfunction in cancer patients receiving immunotherapy with interleukin-2 (IL-2) alone, and to assess the relationship of hypothyroidism to clinical response. A cohort of 281 consecutive patients with metastatic melanoma or renal carcinoma were treated with IL-2 alone from July 1, 1989 until June 30, 1993. The majority (n = 216) received high-dose IL-2 and the remainder (n = 65) received low-dose therapy. Thyroid function was measured before, during, and after immunotherapy. Forty-one percent of initially euthyroid patients developed thyroid dysfunction after starting high-dose IL- 2-alone therapy. The most common abnormality was hypothyroidism, occurring in 35% of patients, although moderate or severe hypothyroidism requiring thyroid hormone replacement occurred in 9% of patients. Hypothyroidism was related to duration of IL-2 therapy and was not associated with clinical response. Hyperthyroidism developed in 7% of previously euthyroid patients receiving high-dose IL-2. Overall, the incidence of thyroid dysfunction was similar in the high- and low-dose IL-2 regimens. In conclusion, thyroid dysfunction is a common sequela of IL-2 therapy. Thyroid function should be measured routinely in cancer patients receiving IL-2-based treatment. It is recommended that thyroid hormone replacement be given to patients with moderate or severe hypothyroidism.

AB - The purpose of this prospective study was to determine the incidence of thyroid dysfunction in cancer patients receiving immunotherapy with interleukin-2 (IL-2) alone, and to assess the relationship of hypothyroidism to clinical response. A cohort of 281 consecutive patients with metastatic melanoma or renal carcinoma were treated with IL-2 alone from July 1, 1989 until June 30, 1993. The majority (n = 216) received high-dose IL-2 and the remainder (n = 65) received low-dose therapy. Thyroid function was measured before, during, and after immunotherapy. Forty-one percent of initially euthyroid patients developed thyroid dysfunction after starting high-dose IL- 2-alone therapy. The most common abnormality was hypothyroidism, occurring in 35% of patients, although moderate or severe hypothyroidism requiring thyroid hormone replacement occurred in 9% of patients. Hypothyroidism was related to duration of IL-2 therapy and was not associated with clinical response. Hyperthyroidism developed in 7% of previously euthyroid patients receiving high-dose IL-2. Overall, the incidence of thyroid dysfunction was similar in the high- and low-dose IL-2 regimens. In conclusion, thyroid dysfunction is a common sequela of IL-2 therapy. Thyroid function should be measured routinely in cancer patients receiving IL-2-based treatment. It is recommended that thyroid hormone replacement be given to patients with moderate or severe hypothyroidism.

KW - Hyperthyroidism

KW - Hypothyroidism

KW - IL-2

KW - Melanoma

KW - Renal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0029550054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029550054&partnerID=8YFLogxK

M3 - Article

C2 - 8680655

AN - SCOPUS:0029550054

VL - 18

SP - 272

EP - 278

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 4

ER -